CYTH vs. TVGN, TARA, ACHL, INKT, INAB, ESLA, PLUR, OKYO, QNCX, and NKGN
Should you be buying Cyclo Therapeutics stock or one of its competitors? The main competitors of Cyclo Therapeutics include Tevogen Bio (TVGN), Protara Therapeutics (TARA), Achilles Therapeutics (ACHL), MiNK Therapeutics (INKT), IN8bio (INAB), Estrella Immunopharma (ESLA), Pluri (PLUR), OKYO Pharma (OKYO), Quince Therapeutics (QNCX), and NKGen Biotech (NKGN). These companies are all part of the "biological products, except diagnostic" industry.
Tevogen Bio (NASDAQ:TVGN) and Cyclo Therapeutics (NASDAQ:CYTH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.
Tevogen Bio has a net margin of 0.00% compared to Tevogen Bio's net margin of -1,864.03%. Cyclo Therapeutics' return on equity of -21.83% beat Tevogen Bio's return on equity.
Cyclo Therapeutics received 6 more outperform votes than Tevogen Bio when rated by MarketBeat users.
In the previous week, Cyclo Therapeutics had 2 more articles in the media than Tevogen Bio. MarketBeat recorded 4 mentions for Cyclo Therapeutics and 2 mentions for Tevogen Bio. Tevogen Bio's average media sentiment score of 0.50 beat Cyclo Therapeutics' score of 0.15 indicating that Cyclo Therapeutics is being referred to more favorably in the news media.
68.6% of Cyclo Therapeutics shares are owned by institutional investors. 56.6% of Tevogen Bio shares are owned by insiders. Comparatively, 29.8% of Cyclo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Tevogen Bio has higher earnings, but lower revenue than Cyclo Therapeutics.
Cyclo Therapeutics has a consensus target price of $3.30, suggesting a potential upside of 161.90%. Given Tevogen Bio's higher probable upside, analysts plainly believe Cyclo Therapeutics is more favorable than Tevogen Bio.
Tevogen Bio has a beta of 0.06, suggesting that its share price is 94% less volatile than the S&P 500. Comparatively, Cyclo Therapeutics has a beta of -0.15, suggesting that its share price is 115% less volatile than the S&P 500.
Summary
Cyclo Therapeutics beats Tevogen Bio on 7 of the 13 factors compared between the two stocks.
Get Cyclo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CYTH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CYTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cyclo Therapeutics Competitors List
Related Companies and Tools
